Otros idiomas TFF Pharmaceuticals, Inc.

Acciones

TFFP

US87241J2033

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:00 08/05/2024			Varia. Cinco días.	Varia. 1 de enero.
2,09 ^USD	-5,00 %		-21,72 %	-70,23 %

30/04	TFF Pharmaceuticals fija el precio de una oferta pública de 4,8 millones de dólares; las acciones bajan antes de la campana	MT
29/04	TFF Pharmaceuticals, Inc. pone a disposición los datos de fase 2 del polvo para inhalación de tacrolimus para la prevención del rechazo del trasplante de pulmón presentados en la reciente reunión anual de la ISHLT	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell	30/04
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering	30/04
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting	29/04
TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting	29/04
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions	16/04
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions	15/04
TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions	15/04
TFF Pharmaceuticals Files Equities Shelf	08/04
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	28/03
Earnings Flash (TFFP) TFF PHARMACEUTICALS Reports Q4 Revenue $114.3M	28/03
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs	27/03
TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs	27/03
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting	25/03
TFF Pharmaceuticals Sells Stock in Registered Direct Offering	20/03
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	20/03
TFF Pharmaceuticals Announces Update on Clinical Programs	20/03
TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs	20/03
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024	14/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas TFF Pharmaceuticals, Inc.

Acciones

TFFP

US87241J2033

Otros idiomas

Filtros